La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Synmosa Biopharma Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Synmosa Biopharma ha un patrimonio netto totale di NT$8.2B e un debito totale di NT$2.4B, che porta il suo rapporto debito/patrimonio netto a 28.6%. Le sue attività totali e le sue passività totali sono rispettivamente NT$12.1B e NT$3.9B. L'EBIT di Synmosa Biopharma è NT$667.9M rendendo il suo rapporto di copertura degli interessi 16.9. Ha liquidità e investimenti a breve termine pari a NT$1.8B.

Informazioni chiave

28.6%

Rapporto debito/patrimonio netto

NT$2.35b

Debito

Indice di copertura degli interessi	16.9x
Contanti	NT$1.83b
Patrimonio netto	NT$8.22b
Totale passività	NT$3.85b
Totale attività	NT$12.07b

Aggiornamenti recenti sulla salute finanziaria

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Jan 05

Recent updates

Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

Apr 04

If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Mar 08

Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 31

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Jan 05

Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

Dec 09

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( NT$4.8B ) di 4114 superano le sue passività a breve termine ( NT$2.2B ).

Passività a lungo termine: Le attività a breve termine di 4114 ( NT$4.8B ) superano le sue passività a lungo termine ( NT$1.7B ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 6.3% ) di 4114 è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di 4114 si è ridotto da 73.7% a 28.6% negli ultimi 5 anni.

Copertura del debito: Il debito di 4114 è ben coperto dal flusso di cassa operativo ( 22.6% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di 4114 sono ben coperti dall'EBIT ( 16.9 x copertura).

Synmosa Biopharma Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Recent updates

Second quarter 2024 earnings released: EPS: NT$0.53 (vs NT$0.42 in 2Q 2023)

Synmosa Biopharma Corporation to Report Q2, 2024 Results on Aug 13, 2024

Dividend of NT$0.60 announced

Synmosa Biopharma Corporation Announces Cash Dividend, Payable on September 13, 2024

First quarter 2024 earnings released: EPS: NT$0.48 (vs NT$0.35 in 1Q 2023)

Synmosa Biopharma Corporation to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: EPS: NT$1.61 (vs NT$2.25 in FY 2022)

Synmosa Biopharma Corporation, Annual General Meeting, May 30, 2024

Synmosa Biopharma Corporation Announces Changes in Fifth Session of the Remuneration Committee

Third quarter 2023 earnings released: EPS: NT$0.35 (vs NT$0.32 in 3Q 2022)

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: NT$0.46 (vs NT$1.13 in 2Q 2022)

Upcoming dividend of NT$0.56 per share at 1.4% yield

Synmosa Biopharma Corporation Announces Cash Dividend, Payable on September 15, 2023

Synmosa Biopharma Corporation Appoints Tu, San-Chien as Additional Independent Director

New minor risk - Shareholder dilution

Synmosa Biopharma Corporation announced that it expects to receive TWD 950 million in funding

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2023

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2023

Investor sentiment improved over the past week

Synmosa Biopharma Corporation Provides Earnings Guidance for the Year 2022

Third quarter 2022 earnings released: EPS: NT$0.35 (vs NT$0.21 in 3Q 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: NT$0.35 (vs NT$0.21 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: NT$1.24 (vs NT$0.23 in 2Q 2021)

Upcoming dividend of NT$0.51 per share

Investor sentiment improved over the past week

Synmosa Biopharma Corporation Announces Changes to the Compensation Committee

First quarter 2022 earnings released: EPS: NT$0.42 (vs NT$0.20 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: NT$1.02 (vs NT$2.20 in FY 2020)

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2022

Third quarter 2021 earnings released: EPS NT$0.24 (vs NT$0.25 in 3Q 2020)

Upcoming dividend of NT$0.30 per share

Second quarter 2021 earnings released: EPS NT$0.29 (vs NT$1.66 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$0.23 (vs NT$0.26 in 1Q 2020)

Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

Synmosa Biopharma Corporation Approves Cash Dividends

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2021

Full year 2020 earnings released: EPS NT$2.46 (vs NT$0.20 in FY 2019)

Revenue beats expectations

If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

New 90-day low: NT$24.05

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

Third quarter 2020 earnings released: EPS NT$0.28

New 90-day high - NT$27.60

Price target raised to NT$28.00

New 90-day high - NT$26.95

First half earnings released

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane